default author photo

Peter F. Billingsley

Sanaria Inc

SCHOLARLY PAPERS

2

DOWNLOADS

267

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Dose-Escalation, Double-Blind, Placebo-Controlled Evaluation of MAM01 Human Monoclonal Antibody for Protection Against Malaria: A First-in-Human, Phase 1 Adaptive Trial

Number of pages: 25 Posted: 23 Jun 2025
Kirsten E. Lyke, Andrea A. Berry, Matthew B. Laurens, Jennifer Winkler, Sudhaunshu Joshi, Abra Rachida Koudjra, Lauryn Butler, Peter F. Billingsley, Tales Pascini, Asha Patil, Kim Lee B. Sim, Grace Fitzgerald, Julie Riegel, Kayla Andrews, Micha Levi, Aparna Anderson, Charles Wells, Hong Liu, James Huleatt and R. Scott Miller
- Center for Vaccine Development and Global Health, - Center for Vaccine Development and Global Health, University of Maryland, Baltimore (UMB) - School of Medicine, affiliation not provided to SSRN, University of Maryland, Baltimore (UMB), University of Maryland, Baltimore (UMB), University of Maryland, Baltimore (UMB), Sanaria Inc, Sanaria Inc, Sanaria Inc, Sanaria Inc, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute and Gates Medical Research Institute
Downloads 201 (380,469)

Abstract:

Loading...

Malaria, Monoclonal antibody, Plasmodium falciparum, Circumsporozoite Protein, Repeat region, MAM01, Phase 1 trial, Subcutaneous, Intravenous

2.

Safety and Efficacy of Two Attenuated PfSPZ Vaccines in Malaria Inexperienced Soldiers Exposed to Plasmodium Falciparum Malaria Genetically Distant from the Vaccine Strain during Deployment to Papua Province, Indonesia

Number of pages: 43 Posted: 25 Feb 2026
Erni J. Nelwan, Thomas L. Richie, Krisin Chand, Khoriah Indrihutami, Agus Rachmat, Mei-Chun Chen, Decy Subekti, Rizka Fahmia, Mutia Rahardjani, Fitria Wulandari, Lenny L. Ekawati, Marillyn M. Tamburian, Saraswati Soebianto, Yulia Widya Santy, Tooba Murshedkar, Yonas Abebe, Natasha KC, Eric R. James, Peter F. Billingsley, Iqbal RF Elyazar, Luke Ho, Sky Chi-Tian Chen, Yogi Ertanto, Waras Budiman, Ankit Dwivedi, Joana C. Silva, Kim Lee B. Sim, Irwan Suriswan, I. Made Mardika, Inge Sutanto, Rintis Noviyanti, Noch T. Mallisa, Ari F. Syam, Amin Soebandrio, J. Kevin Baird and Stephen Hoffman
Universitas Indonesia (UI), Sanaria Inc, Universitas Indonesia (UI), Universitas Indonesia (UI), Universitas Indonesia (UI), Sanaria Inc, Universitas Indonesia (UI), Universitas Indonesia (UI), Universitas Indonesia (UI), Universitas Indonesia (UI), Universitas Indonesia (UI), Universitas Indonesia (UI), Universitas Indonesia (UI), Universitas Indonesia (UI), Sanaria Inc, Sanaria Inc, Sanaria Inc, Sanaria Inc, Sanaria Inc, Eijkman-Oxford Clinical Research Unit (EIMB), StatPlus Inc., StatPlus Inc., Government of the Republic of Indonesia, Muhammadiyah University, University of Maryland, University of Maryland, Sanaria Inc, Gatot Soebroto Army Hospital, Gatot Soebroto Army Hospital, Universitas Indonesia (UI), National Research and Innovation Agency (BRIN), Government of the Republic of Indonesia, Universitas Indonesia (UI), Universitas Indonesia (UI), Universitas Indonesia (UI) and Sanaria Inc
Downloads 66 (989,921)

Abstract:

Loading...

Plasmodium falciparum, PfSPZ Vaccine, PfSPZ-CVac, malaria vaccine, deployment, soldiers, vaccine efficacy, vaccine safety, Indonesia, Papua, cross-strain immunity